신규항암제인 Heptaplatin의 인체 흑색종세포 (SK-MEL-28)에 대한 세포생존률 및 유세포 분석

• 영문명: Cell Viability and Flow Cytometry Analysis of a Novel Antitumor Agent, Heptaplatin in Human Melanoma Cell Line, SK-MEL-28
• 발행기관: 대한약학회
• 저자명: 최수라(Su-La Choi) 명평근(Pyung-Keun Myung)
• 간행물 정보: 『약학회지』제47권 제6호 (2003년), 345~351쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2003.12.31

영문 초록

Heptaplatin, cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II), is a novel platinum-based antitumor agent with clinical potential against human stomach cancer and the 3rd generation of the cisplatin. This study was performed to study how cisplain, heptaplatin and sunpla which is a mixture of heptaplatin and mannitol (w:w=1:2) affect cell viability of SK-MEL-28 human melanoma cell line. Heptaplatin (IC50; 95.35 μM) and sunpla (IC50; 10.95 μM) were less effect than cisplatin (IC50; 10.92 μM) on the SK-MEL-28 cells. By cell cycle analysis using flow cytometry, it was identified that the cells were arrested at G2/M phase by cisplatin, heptaplatin and sunpla, and percentage of cell death group was increased according to increasing of time and concentration. These results suggest that cisplatin, heptaplatin and sunpla are a novel anticancer agent against human melanoma cell.

키워드

cisplatin heptaplatin sunpla cell viability flow cytometry.